Sangamo and Genentech Partner on $50M Upfront, $1.9B Genomic Medicines Deal

Aug 6, 2024, 12:27 PM

Sangamo Therapeutics has announced a global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. The deal includes $50 million in near-term upfront license fees and milestone payments, with potential development and commercial milestone payments of up to $1.9 billion. The agreement involves the use of Sangamo's ZF-repressors and STAC-BBB AAV delivery systems targeting tau and another undisclosed neurodegenerative condition. The tau-repressor therapy was previously part of a 2020 partnership with Biogen. This partnership aims to advance the development of genomic medicines for conditions such as Alzheimer's disease. The cash-strapped Sangamo expects this deal to extend its runway.